alr technologies inc (ALRT) Key Developments
ALR Technologies Inc. to Conduct Clinical Trial with Premier Hospital of Chilean Health Ministry in Santiago
Aug 11 14
ALR Technologies Inc. (ALRT) announced that it had signed a memorandum of understanding with the Hospital Clínico Metropolitano La Florida to conduct a clinical outcomes study utilizing ALRT's Health-e-Connect Diabetes Management System. The trial will also utilize ALRT's latest product offering, the Insulin Dose Adjustment Consult (IDAC) feature that allows primary care physicians to access electronically an insulin dose recommended by an endocrinologist. Hospital Clínico Metropolitano La Florida will enroll 100 of its insulin-requiring patients in the intervention arm of the study and 100 insulin-requiring patients in the control arm. The intervention group will utilize the Health-e-Connect System with IDAC for six months of treatment. Key data points for the study will include: average A1c reduction, adherence to medication and care plan, and physician and patient satisfaction. The trial will be designed so that its results can be published in a premier academic medical journal with authors affiliated with both ALRT and Hospital La Florida.
ALR Technologies Inc. Appoints Peter H. Stafford to the Board of Directors
Aug 8 14
ALR Technologies Inc. announced that on August 1, 2014, Mr. Peter H. Stafford, QC was appointed to the company's board of directors. Mr. Stafford has not been appointed to any of the committees of the board. Mr. Stafford is a retired lawyer and business consultant, having practised with Fasken Martineau DuMoulin LLP, and its predecessor firms, from 1966 to 2013, except for several years spent as in-house counsel for clients of the firm.
ALR Technologies Inc. Announces Management Changes
May 21 14
ALR Technologies Inc. confirmed that Mr. Weinstein has resigned from the positions of president, chief operating officer and member of board of directors. The board of directors appointed William Smith as president effective May 19, 2014.
ALR Technologies Inc. Upgrades Health-e-Connect Diabetes Management System
May 7 14
ALR Technologies Inc. announced that it has upgraded its Health-e-Connect Diabetes Management System in order to facilitate online, insulin dosing consultations for physicians. Through ALRT's Health-e-Connect System, prescribing physicians will have the option to receive an online second opinion on their recommended insulin dose from an independent consulting endocrinologist. The consulting endocrinologist will provide the dosing opinion based on a review of actual blood glucose data from the patient's meter in combination with other important factors necessary for prescribing, such as current insulin dosage, height and weight. ALRT's Health-e-Connect Diabetes Management System is an ideal tool to assist providers with an online second opinion as patient blood glucose data and other key information can be made available online to the consulting specialist. Such a tool creates an easy method to allow a prescribing clinician to regularly adjust a patient's insulin dose without an office visit. The Insulin Dose Adjustment Consultation (IDAC) system is in the final testing phase with expected customer availability in mid-June. This new feature will provide many more physicians with the capability to intensively manage the blood glucose of their patients as ALRT's Diabetes Care Facilitators will monitor patient blood glucose levels, helping to spot trends in the data that may require a dose adjustment. As the number of patients with diabetes is expected grow and the shortage of physicians accelerates, providers will be able to care for more patients without sacrificing the quality of care. For patients, the regular adjustment of their insulin dose holds the potential that their insulin dose may be optimized on a regular basis, which may slow the progression of some comorbidities associated with diabetes. Additionally, with the monitoring and care facilitation embedded in the Health-e-Connect System, patients may also find it easier to adhere to their insulin regimen. Finally, for payers, the widespread adoption of intensive blood glucose management would be a key tool in helping to manage the escalating costs of diabetes care without the cost of additional specialist office visits. The proper dosing of insulin is one of the most important challenges in the clinical practice of diabetes. Insulin doses that are too low result in poor glucose control, leading to significant microvascular complications and comorbidities. Insulin doses that are too high can cause hypoglycemia, risking adverse events such as unconsciousness, coma and even death. Besides these serious health consequences for patients, the poor outcomes produced by improper insulin dosing lead to significant, unnecessary healthcare costs.
ALR Technologies Inc. Appoints William S. Smith as President, Effective May 19, 2014
Apr 18 14
ALR Technologies Inc. announced that William S. Smith has been appointed President of the company, effective May 19, 2014. Mr. Lawrence Weinstein, who served as President & COO of ALR Technologies since 2010, expressed a wish to pursue other activities and will remain as a consultant. Mr. Smith has served as Director, Commercial Strategies and External Affairs at ALR Technologies since February 2013. Prior to joining ALRT, he worked at senior levels in the private sector and in government for more than two decades.